Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marker linked with most deadly brain tumours:

This article was originally published in Clinica

Executive Summary

A US research team has identified what could be a marker for some of the most prevalent and difficult-to-manage forms of brain tumour - human high-grade gliomas. In a study of tumours from 23 patients with glioblastoma multiforme, the team found that more than 90% of patients possessed a receptor for an immune regulatory factor, interleukin 13. The study, led by Dr Waldemar Debinski of the Penn State's College of Medicine in Hershey, Pennsylvania, is published in the May issue of Clinical Cancer Research.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel